Fig. 5.

Antitumor activity of the APBC in B16F10-hPD-L1 tumor-bearing C57BL/6 mice models. (A) Flow cytometry analysis of mPD-L1 expression on B16F10-hPD-L1 cells. (B) Flow cytometry analysis of hPD-L1 expression on B16F10-hPD-L1 cells. (C) Representative images of subcutaneous tumors harvested at day 24. (D) Tumor volume changes measured over time in the vehicle (n = 10), APBC 10 mg/kg (n = 5), APBC 15 mg/kg (n = 10), Atezolizumab 10 mg/kg (n = 6) groups. (E) Weight of tumors at day 24 after tumor inoculation. (F) Spleen weight at day 24 after tumor inoculation. All quantitative data are represented as means ± SEM, *P< 0.05, **P< 0.01, ***P< 0.001, unpaired t test.